CO2017013720A2 - Composiciones y métodos para tratar la enfermedad celiaca - Google Patents

Composiciones y métodos para tratar la enfermedad celiaca

Info

Publication number
CO2017013720A2
CO2017013720A2 CONC2017/0013720A CO2017013720A CO2017013720A2 CO 2017013720 A2 CO2017013720 A2 CO 2017013720A2 CO 2017013720 A CO2017013720 A CO 2017013720A CO 2017013720 A2 CO2017013720 A2 CO 2017013720A2
Authority
CO
Colombia
Prior art keywords
methods
compositions
seq
celiac disease
residue
Prior art date
Application number
CONC2017/0013720A
Other languages
English (en)
Inventor
Ingrid Swanson Pultz
Clancey Wolf
Justin Bloomfield Siegel
Christine Elaine Tinberg
Lance Stewart
David Baker
Original Assignee
Univ California
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Univ Washington filed Critical Univ California
Publication of CO2017013720A2 publication Critical patent/CO2017013720A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Abstract

Los polipéptidos y métodos para su uso, se divulgan teniendo la secuencia de aminoácido por lo menos 75% idéntica a la secuencia de aminoácido de la SEQ ID NO:1, se proporcionan, en donde (a) el polipéptido degrada un PFQPQLPY (SEQ ID NO: 140) péptido y/o un PFPQPQQPF (SEQ ID NO: 68) a pH 4; (b) residuo 467 es Ser, residuo 267 es Glu y residuo 271 es Asp; y (c) el polipéptido comprende un cambio del aminoácido de la SEQ ID NO: 1 en uno o más residuos seleccionado del grupo que consistente en 221, 262E, 268, 269, 270, 319A, 320, 354E/Q/R/Y, 358S/Q/T, 368F/Q, 399, 402, 406, 424, 449, 461, 463, 105, 171, 172, 173, 174 y 456.
CONC2017/0013720A 2015-06-08 2017-12-28 Composiciones y métodos para tratar la enfermedad celiaca CO2017013720A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562172557P 2015-06-08 2015-06-08
PCT/US2016/036356 WO2016200880A1 (en) 2015-06-08 2016-06-08 Compositions and methods for treating celiac sprue disease

Publications (1)

Publication Number Publication Date
CO2017013720A2 true CO2017013720A2 (es) 2018-04-10

Family

ID=56194586

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0013720A CO2017013720A2 (es) 2015-06-08 2017-12-28 Composiciones y métodos para tratar la enfermedad celiaca

Country Status (24)

Country Link
US (4) US10793846B2 (es)
EP (1) EP3302518A1 (es)
JP (3) JP7325030B2 (es)
KR (1) KR20180023903A (es)
CN (1) CN107873053A (es)
AU (2) AU2016276436B2 (es)
BR (1) BR112017026142A2 (es)
CA (1) CA2988651A1 (es)
CL (1) CL2017003097A1 (es)
CO (1) CO2017013720A2 (es)
CR (1) CR20170567A (es)
DO (1) DOP2017000286A (es)
EA (1) EA037603B1 (es)
EC (1) ECSP17080844A (es)
HK (1) HK1245129A1 (es)
IL (2) IL256103B (es)
MX (2) MX2017015786A (es)
MY (1) MY189160A (es)
PE (1) PE20180509A1 (es)
PH (1) PH12017502213A1 (es)
SA (1) SA517390479B1 (es)
SG (1) SG10201911867YA (es)
TN (1) TN2017000520A1 (es)
WO (1) WO2016200880A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3033100B1 (en) 2013-08-14 2018-10-03 University Of Washington Through Its Center For Commercialization Compositions for treating celiac sprue disease
WO2016200880A1 (en) * 2015-06-08 2016-12-15 University Of Washington Compositions and methods for treating celiac sprue disease
JP7202893B2 (ja) 2016-06-12 2023-01-12 武田薬品工業株式会社 炎症性腸疾患を治療する方法
KR102553627B1 (ko) 2016-12-22 2023-07-07 에베 누트리찌온 게엠베하 안정한 프로테아제 변이체
TW202233834A (zh) 2020-10-30 2022-09-01 華盛頓大學 用於治療乳糜瀉的組合物及方法
JP7268911B2 (ja) * 2021-09-16 2023-05-08 株式会社ユニバーサルエンターテインメント 遊技機
JP7268910B2 (ja) * 2021-09-16 2023-05-08 株式会社ユニバーサルエンターテインメント 遊技機

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688229B1 (fr) 1992-03-09 1995-06-23 Ulice Soc Procede de synthese enzymatique d'esters alkyliques de peptides, produits ainsi obtenus et utilisation desdits produits.
JP2002078489A (ja) * 2000-09-04 2002-03-19 Daiwa Kasei Kk セリン残基が活性発現に関与する新規酸性プロテアーゼ
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
ES2361993T5 (es) 2002-02-14 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Tratamiento con enzimas de productos alimenticios para celiaquía
US7265093B2 (en) 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
AU2003234597A1 (en) 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
EP1563300B1 (en) 2002-11-20 2012-04-18 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7628985B2 (en) 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
US7563864B2 (en) 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7534426B2 (en) 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
EP1600141B1 (en) * 2004-05-24 2013-04-17 3M Deutschland GmbH Collagenolytic active enzyme containing compositions for the treatment of dental caries
EP1726643A1 (en) 2005-05-27 2006-11-29 Direvo Biotech AG Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances
WO2010021752A1 (en) 2008-08-21 2010-02-25 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
HU0900199D0 (en) * 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis of gluten-induced autoimmune diseases
CN102858795A (zh) * 2010-02-02 2013-01-02 天野酶制品美国有限公司 蛋白酶针对谷蛋白不耐受的用途
TR201806885T4 (tr) 2011-08-10 2018-06-21 Univ Washington Through Its Center For Commercialization Çölyak sprue hastalığının tedavisi için bileşimler ve yöntemler.
AU2012348782B2 (en) 2011-12-06 2017-10-26 Fondazione Istituto Insubrico Di Ricerca Per La Vita New proteases able to hydrolyze gluten peptides and proteins at acidic pH, from the Actinomycete Actinoallomurus
EP3033100B1 (en) 2013-08-14 2018-10-03 University Of Washington Through Its Center For Commercialization Compositions for treating celiac sprue disease
KR102288722B1 (ko) * 2013-08-30 2021-08-12 모멘티브 퍼포먼스 머티리얼즈 인크. 아미노산을 갖는 수분 경화성 화합물
WO2016200880A1 (en) * 2015-06-08 2016-12-15 University Of Washington Compositions and methods for treating celiac sprue disease

Also Published As

Publication number Publication date
AU2016276436B2 (en) 2022-07-07
CA2988651A1 (en) 2016-12-15
MY189160A (en) 2022-01-29
CR20170567A (es) 2018-06-14
JP2018517409A (ja) 2018-07-05
EP3302518A1 (en) 2018-04-11
AU2016276436A1 (en) 2017-12-07
JP2024041995A (ja) 2024-03-27
EA201792362A8 (ru) 2018-12-28
US10793846B2 (en) 2020-10-06
EA201792362A1 (ru) 2018-05-31
DOP2017000286A (es) 2018-03-30
MX2022005483A (es) 2022-06-02
CL2017003097A1 (es) 2018-06-29
US10988748B2 (en) 2021-04-27
JP2021151250A (ja) 2021-09-30
KR20180023903A (ko) 2018-03-07
EA037603B1 (ru) 2021-04-20
BR112017026142A2 (pt) 2018-08-14
US20200109387A1 (en) 2020-04-09
US20210171928A1 (en) 2021-06-10
IL256103B (en) 2022-01-01
WO2016200880A1 (en) 2016-12-15
IL256103A (en) 2018-02-28
JP7325030B2 (ja) 2023-08-14
SG10201911867YA (en) 2020-01-30
TN2017000520A1 (en) 2019-04-12
JP7429907B2 (ja) 2024-02-09
US20180142226A1 (en) 2018-05-24
ECSP17080844A (es) 2018-03-31
SA517390479B1 (ar) 2022-11-10
US11485961B2 (en) 2022-11-01
US20230130764A1 (en) 2023-04-27
AU2022241520A1 (en) 2022-10-27
CN107873053A (zh) 2018-04-03
HK1245129A1 (zh) 2018-08-24
IL288768A (en) 2022-02-01
PE20180509A1 (es) 2018-03-09
MX2017015786A (es) 2018-12-11
PH12017502213A1 (en) 2018-06-11

Similar Documents

Publication Publication Date Title
CO2017013720A2 (es) Composiciones y métodos para tratar la enfermedad celiaca
EA202090090A1 (ru) Включение неприродных нуклеотидов и способы с ними
EA202091710A1 (ru) Антитела против cd73 и способы их применения
NI201600028A (es) Polipéptido para la escisión hidrolítica de la zearalenona y/o derivados de la zearalenona, polinucleótido aislado de la misma y poliéptido que contiene aditivo, uso y procedimiento de los mismos.
MX2017016105A (es) Polinucleotidos y polipeptidos de adenovirus.
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
BR112017007816A2 (pt) composições farmacêuticas compreendendo variantes de peptídeos e métodos de uso das mesmas
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
BR112019011860A2 (pt) proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune
AR102445A1 (es) COMPOSICIONES Y MÉTODOS RELACIONADOS CON b-GLUCOSIDASA
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
CU20170112A7 (es) Variantes de polipeptidos que dividen toxinas de fusarium, aditivo que contiene estas variantes y su uso, así como procedimientos para la división de toxinas de fusarium
BR112018013246A2 (pt) rótulo de peptídeo e proteína rotulada incluindo o mesmo
PE20181956A1 (es) Polipeptidos que inhiben cd40l
UY36616A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
CO2017013404A2 (es) Variantes de il-37
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
AR102061A1 (es) Genes de chromobacterium subtsugae
PE20190967A1 (es) Aislados modificados de streptomyces fungicidicus y su uso
NZ754781A (en) Thrombin inhibitors for treatment of stroke and related coagulative disorders
BR112018075613A2 (pt) peptídeos para o tratamento de osteoartrite
PE20190104A1 (es) Antigenos y anticuerpos de chagas y composiciones, metodos y usos de los mismos
EA039001B9 (ru) Аденовирусные полинуклеотиды и полипептиды
BR112022005036A2 (pt) Composições e métodos relacionados a construtos de domínio de ligação de antígeno-fc projetados direcionados a cd38
AR109156A1 (es) Procedimiento de limpieza y clasificación granulométrica de áridos mediante el uso de hidrociclones a bordo de buques